164 related articles for article (PubMed ID: 9862252)
1. The effects of age and gender on the pharmacokinetics of irbesartan.
Vachharajani NN; Shyu WC; Smith RA; Greene DS
Br J Clin Pharmacol; 1998 Dec; 46(6):611-3. PubMed ID: 9862252
[TBL] [Abstract][Full Text] [Related]
2. The pharmacokinetics and pharmacodynamics of irbesartan in heart failure.
Kostis JB; Vachharajani NN; Hadjilambris OW; Kollia GD; Palmisano M; Marino MR
J Clin Pharmacol; 2001 Sep; 41(9):935-42. PubMed ID: 11549097
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and pharmacodynamics of irbesartan in healthy subjects.
Marino MR; Langenbacher K; Ford NF; Uderman HD
J Clin Pharmacol; 1998 Mar; 38(3):246-55. PubMed ID: 9549663
[TBL] [Abstract][Full Text] [Related]
4. Oral bioavailability and disposition characteristics of irbesartan, an angiotensin antagonist, in healthy volunteers.
Vachharajani NN; Shyu WC; Chando TJ; Everett DW; Greene DS; Barbhaiya RH
J Clin Pharmacol; 1998 Aug; 38(8):702-7. PubMed ID: 9725545
[TBL] [Abstract][Full Text] [Related]
5. The pharmacokinetics of irbesartan in renal failure and maintenance hemodialysis.
Sica DA; Marino MR; Hammett JL; Ferreira I; Gehr TW; Ford NF
Clin Pharmacol Ther; 1997 Dec; 62(6):610-8. PubMed ID: 9433389
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic properties and bioequivalence of two irbesartan/ hydrochlorothiazide fixed-dose combination tablets in healthy male Chinese volunteers.
Liu J; Wu L; Hu X; Wu G; Zheng Y; Zhou H; Zhai Y; Zhu M; ShenTu J
Int J Clin Pharmacol Ther; 2015 Jul; 53(7):573-81. PubMed ID: 25828636
[TBL] [Abstract][Full Text] [Related]
7. The pharmacokinetics of irbesartan in hypertensive children and adolescents.
Sakarcan A; Tenney F; Wilson JT; Stewart JJ; Adcock KG; Wells TG; Vachharajani NN; Hadjilambris OW; Slugg P; Ford NF; Marino MR
J Clin Pharmacol; 2001 Jul; 41(7):742-9. PubMed ID: 11452706
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and bioequivalence study of irbesartan tablets after a single oral dose of 300 mg in healthy Thai volunteers.
Wittayalertpanya S; Chariyavilaskul P; Prompila N; Sayankuldilok N; Eiamart W
Int J Clin Pharmacol Ther; 2014 May; 52(5):431-6. PubMed ID: 24725445
[TBL] [Abstract][Full Text] [Related]
9. CYP2C9 3 and 13 alleles significantly affect the pharmacokinetics of irbesartan in healthy Korean subjects.
Choi CI; Kim MJ; Chung EK; Lee HI; Jang CG; Bae JW; Lee SY
Eur J Clin Pharmacol; 2012 Feb; 68(2):149-54. PubMed ID: 21842338
[TBL] [Abstract][Full Text] [Related]
10. Modeling of the pharmacokinetic/pharmacodynamic interaction between irbesartan and hydrochlorothiazide in normotensive subjects.
Hedaya MA; Helmy SA
Biopharm Drug Dispos; 2015 May; 36(4):216-31. PubMed ID: 25545238
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and pharmacodynamics of irbesartan in patients with hepatic cirrhosis.
Marino MR; Langenbacher KM; Raymond RH; Ford NF; Lasseter KC
J Clin Pharmacol; 1998 Apr; 38(4):347-56. PubMed ID: 9590462
[TBL] [Abstract][Full Text] [Related]
12. The new angiotensin II receptor antagonist, irbesartan: pharmacokinetic and pharmacodynamic considerations.
Brunner HR
Am J Hypertens; 1997 Dec; 10(12 Pt 2):311S-317S. PubMed ID: 9438775
[TBL] [Abstract][Full Text] [Related]
13. Lack of effect of food on the oral bioavailability of irbesartan in healthy male volunteers.
Vachharajani NN; Shyu WC; Mantha S; Park JS; Greene DS; Barbhaiya RH
J Clin Pharmacol; 1998 May; 38(5):433-6. PubMed ID: 9602956
[TBL] [Abstract][Full Text] [Related]
14. Irbesartan does not affect the steady-state pharmacodynamics and pharmacokinetics of warfarin.
Mangold B; Gielsdorf W; Marino MR
Eur J Clin Pharmacol; 1999 Oct; 55(8):593-8. PubMed ID: 10541778
[TBL] [Abstract][Full Text] [Related]
15. Disposition of irbesartan, an angiotensin II AT1-receptor antagonist, in mice, rats, rabbits, and macaques.
Davi H; Tronquet C; Miscoria G; Perrier L; DuPont P; Caix J; Simiand J; Berger Y
Drug Metab Dispos; 2000 Jan; 28(1):79-88. PubMed ID: 10611144
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of candesartan after single and repeated doses of candesartan cilexetil in young and elderly healthy volunteers.
Hübner R; Högemann AM; Sunzel M; Riddell JG
J Hum Hypertens; 1997 Sep; 11 Suppl 2():S19-25. PubMed ID: 9331000
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of the acute effects of angiotensin II by the receptor antagonist irbesartan in normotensive men.
Ribstein J; Picard A; Armagnac C; Sissmann J; Mimran A
J Cardiovasc Pharmacol; 2001 Apr; 37(4):449-60. PubMed ID: 11300658
[TBL] [Abstract][Full Text] [Related]
18. Study on the pharmacokinetics and relative bioavailability of irbesartan capsules in healthy volunteers.
Gu S; Chen H; Qiu Y; Shi S; Zeng F
J Huazhong Univ Sci Technolog Med Sci; 2002; 22(1):14-6. PubMed ID: 12658772
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of irbesartan are not altered in special populations.
Marino MR; Vachharajani NN
J Cardiovasc Pharmacol; 2002 Jul; 40(1):112-22. PubMed ID: 12072584
[TBL] [Abstract][Full Text] [Related]
20. Human pharmacokinetic/pharmacodynamic profile of irbesartan: a new potent angiotensin II receptor antagonist.
Ruilope L
J Hypertens Suppl; 1997 Dec; 15(7):S15-20. PubMed ID: 9532516
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
